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ABSTRACT
Objectives: The purpose of the present in vivo study was to evaluate whether pericard collagen membranes coated with 
ancillary amounts of testosterone and alendronate in a poly-lactic glycolic acid (PLGA) carrier as compared to uncoated 
membranes will improve early bone regeneration.
Material and Methods: In each of 16 minipigs, four standardized mandibular intraosseous defects were made bilaterally. 
The defects were filled with Bio-Oss® granules and covered with a non-coated or coated membrane. Membranes were spray-
coated with 4 layers of PLGA containing testosterone and alendronate resulting in 20, 50 or 125 μg/cm2 of testosterone and 
20 µg/cm2 alendronate (F20, F50, F125). Non-coated membranes served as controls (F0). Animals were sacrificed at 6 and 12 
weeks after treatment. Qualitative and quantitative histological evaluations of bone regeneration were performed. Differences 
between groups were assessed by paired Student’s t‐test. 
Results: Light microscopical analysis showed new bone formation that was in close contact with the Bio-Oss® surface without 
an intervening non-mineralized tissue layer. Histomorphometric analysis of newly formed bone showed a significant 20% 
increase in area in the F125 coated membrane treated defects (40 [SD 10]%) compared to the F0 treated defects after 6 weeks 
(33 [SD 10]%, P = 0.013). At week 12, the total percentage  of new bone was increased compared to week 6, but no increase 
in newly formed bone compared to F0 was observed.
Conclusions: The data from this in vivo study indicate that F125 collagen membranes coated with testosterone and alendronate 
resulted in superior bone formation (+24%) when normalized to control sites using uncoated membranes. 
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INTRODUCTION
After tooth extraction, dimensions of the alveolar 
ridge and extraction socket significantly change 
because of a naturally occurring bone remodelling 
process [1]. A 50% reduction in alveolar ridge width 
and height has been reported to occur within one 
year after tooth extraction [2]. Ridge dimensions are 
critical in implant therapy, as a reduced alveolar ridge 
poses a major limitation in the installation of dental 
implants [3]. As a consequence, bone regeneration 
procedures have been introduced to increase the 
ridge width and height to facilitate dental implant 
placement. The majority of guided bone regeneration 
(GBR) procedures involve the use of bone grafts and 
barrier membranes, which entails the installation 
of a bone graft particulate into the bone defect and 
coverage of the outside with a membrane to prevent 
ingrowth of soft tissues. The efficacy of this procedure 
has already been proven in multiple clinical studies, 
in which a wide variety of graft materials as well 
as membranes has been applied [4-7]. In GBR, 
the function of the bone graft material is to act as a 
scaffold for bone ingrowth. The primary function of 
the membrane is to act as a barrier that prevents soft 
tissue ingrowth between the graft granules. 
Despite the reported favourable effect, there are also 
a lot of studies that are critical about the outcome and 
clinical predictability of these GBR and augmentation 
procedures [8,9]. It is recommended that further 
studies are done to optimize the osteogenic properties 
of the materials as used in these procedures [10]. In 
view of this, experiments have already been done 
using biomolecules (e.g. bone morphogenetic protein 
2 [BMP2]) or mesenchymal stem cells to support 
alveolar bone regeneration. However, the final clinical 
effectiveness of these therapies is not evident and 
there is concern about the complexity, safety and costs 
of the involved processes [11-13]. Therefore, there is 
need to alternative simple and less costly materials, 
which still improve significantly the outcome of bone 
regeneration procedures.
Given the above mentioned, an experimental strategy 
to favour early bone formation in bone regeneration 
procedures involves the use of anti-osteoporotic 
drugs [14]. Such drugs are used to treat abnormal 
bone metabolism, like in osteoporosis. The drugs 
interfere in the bone turnover process by reducing 
bone breakdown and by stimulating bone deposition 
[15,16]. The most frequently used drugs belong 
to the class of bisphosphonates, e.g. alendronate 
and zoledronic acid, which are highly potent in the 
inactivation of osteoclast activity.
The anti-osteoporotic agents can be given alone as 
single drug therapy or as combination therapy in 
which different osteoanabolic agents (e.g. teriparatide, 
abolaparatide and romosozumab) are combined to 
achieve a supplementary effect on increase of the bone 
mass [16,17]. In fact, the combination of using both 
an anabolic and catabolic compound to improve local 
bone formation has previously been shown to result in 
synergistic effects on fracture healing [18]. Another 
important osteoanabolic agent is testosterone, as it 
directly stimulates the proliferation and differentiation 
of osteoblast cells [19,20]. In a critical-sized femoral 
segmental defect the local delivery of testosterone was 
effective in stimulating bone healing [21]. Recently, it 
was suggested to apply a similar combination therapy 
approach for bone regeneration using testosterone 
and alendronate [22]. The concept is based on the 
application of a poly-lactic glycolic acid (PLGA) 
solution containing testosterone and alendronate 
in ancillary amounts to activate osteoblasts and 
inhibit osteoclasts, respectively. Due to the observed 
synergistic effect of using alendronate in combination 
with testosterone significant effects on bone formation 
and bone mineral density (BMD) have been described 
[22]. The hypothesized advantage of using PLGA 
as a carrier is that a controlled and sustained release 
of testosterone and alendronate will be obtained. 
Controlled release of alendronate however, is not 
considered important due to the inherent characteristic 
of alendronate, unlike testosterone, to immediately 
bind to hydroxyapatite present in bone tissue. Studies 
using local application of bisphosphonates for bone 
healing have shown detrimental effects when using 
high concentrations. For this reason, alendronate was 
added in a fixed, optimal amount of 20 µg/cm2. 
To study the synergistic effects of testosterone 
and alendronate in vitro bone explant studies were 
performed. Bone explants contain both osteoblasts and 
osteoclasts and hence can be used to simultaneously 
study the effects of anabolic and catabolic compounds 
independently and in combination. Moreover, as 
bone explants can be cultured up to 4 weeks bone 
biomarkers secreted into the culture medium can 
be measured over time and the bone explants can be 
analysed by µCT to determine the effects on various 
bone parameters such BMD and bone volume [23]. 
Consequently, the aim of the present study was to 
evaluate whether guided bone regeneration using 
collagen membranes coated with ancillary amounts of 
testosterone and alendronate in a poly-lactic glycolic 
acid carrier as compared to uncoated membranes will 
improve early bone formation. Therefore, an in vitro 
study with bone biopsies as well as an in vivo study in 
minipigs was performed.
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MATERIAL AND METHODS
In vitro study on bone explants
Porcine bone specimens
Bone biopsies were taken from fresh porcine knees 
obtained at a local abattoir. Three cylindrical bone 
biopsies (7 mm diameter) per condyle were taken 
from the femur with a trephine drill. The biopsies 
were washed two times with phosphate buffered 
saline (PBS) before they were cultured in alpha-
minimum essential medium (α-MEM) (Invitrogen 
Corp.; Carlsbad, CA, USA) supplemented with 100 
U/ml penicillin, 100 µg/ml streptomycin (Invitrogen) 
and 10% fetal bovine serum (Hyclone™ - GE 
Healthcare; Chicago, IL, USA), 50 μg/ml ascorbic 
acid (Sigma-Aldrich Co.; St. Louis, MO, USA), 10 
nM β-glycerolphosphate (Sigma-Aldrich) and 75 nM 
dihydrotestosterone (Tokyo Chemical Industry Co.; 
Tokyo, Japan), 2 µM alendronate (Tokyo Chemical 
Industry Co.) or a combination of both. Biopsies were 
cultured under standard culturing conditions (37 °C, 
5% CO2 and 95% humidity) and medium (including 
dihydrotestosterone and alendronate) was replaced 
twice per week. Following 7 days of culturing, the 
alkaline phosphatase (ALP) activity in the culture 
medium was determined with a luminescence assay 
(CDP-Star®, ready-to-use - F. Hoffmann-La Roche 
Ltd; Basel, Switzerland). After 4 weeks, biopsies 
were scanned with µCT (Skyscan 1076 system - 
Bruker-MicroCT; Kontich, Belgium) with a voxel 
size of 9 µM, an energy of 59 kVp; a current of 200 
μA; and an integration time of 2200 ms. The scans 
were reconstructed with NRecon software (Bruker-
microCT) and analysed with CTan software (Bruker-
microCT) to assess bone volume fraction (BV/TV), 
bone surface density (BS/TV), trabecular thickness 
(Tb.Th), trabecular separation (Tb.Sp) and trabecular 
number (Tb.N) in the trabecular bone. Following 
µCT, bone strength of the biopsies was measured 
using a compression test (H10KT - Hounsfield Test 
Equipment Ltd.; Redhill, UK). The compression 
assay was performed by using a pre-load of 1 N and 
a cross-head speed of 1 mm/s. The compression load-
displacement curves obtained during this test were 
further used to calculate the compression strength (σᵨ).
Human bone specimens
Human bone biopsies were taken from femur material 
obtained from osteoarthritic (OA) patients that 
underwent knee replacement surgery at the Radboud 
University Medical Center (n = 13 patients). Multiple 
cylindrical bone biopsies (7 mm in diameter) were 
taken with a hollow pipe and biopsies were washed 
two times with PBS before they were cultured in 
α-MEM (Invitrogen) supplemented with 100 U/
ml penicillin, 100 µg/ml streptomycin (Invitrogen), 
amphotericine 2.5 µg/ml (Sigma-Aldrich) and 10% 
fetal bovine serum (Hyclone™), 50 μg/ml ascorbic 
acid (Sigma-Aldrich) and 10 nM β-glycerolphosphate 
(Sigma-Aldrich). From each donor 3 - 10 biopsies 
(65 biopsies in total) were used as control and 3 - 8 
biopsies were treated with 75 nM dihydrotestosterone 
(Tokyo Chemical Industry) and 2 µM alendronate 
(Tokyo Chemical Industry), which was added to the 
culture medium. Biopsies were cultured under standard 
conditions (37 °C, 5% CO2 and 95% humidity) 
and medium (including dihydrotestosterone and 
alendronate) was replaced twice per week. After 4 
weeks, biopsies were scanned with µCT (Skyscan 
1076 system - Bruker-MicroCT) with a voxel size 
of 9 µM, an energy of 59 kVp; a current of 200 μA; 
and an integration time of 2200 ms. The scans were 
reconstructed with NRecon and analysed with CTan 
software (Bruker-MicroCT) to assess BV/TV, BS/TV, 
Tb.Th, Tb.Sp, Tb.N and BMD in the trabecular bone 
and the average of the control and treated group of 
each donor was calculated.
In vivo minipig study
Preparation and characterization of pericardium 
membranes
Non-sterilized Good Manufacturing Produced porcine 
pericardium membranes (4 x 3 cm) (European 
Medical Contract Manufacturing; Nijmegen, The 
Netherlands) were coated on the rough side using 
a Prism 500 ultrasonic spray coater (Ultrasonic 
Systems Inc.; Haverhill, MA, USA). Membranes were 
coated with 4 layers of acetonitrile containing 5% 
PLGA (PURASORB PDLG 5004A - Corbion Group 
Netherlands B.V.; Amsterdam, The Netherlands), 
testosterone and micronized alendronate resulting 
in 20, 50 or 125 μg/cm2 of testosterone (Aspen 
Pharmacare; Durban, South Africa) and 20 μg/
cm2 alendronate (Polpharma; Starogard Gdański, 
Poland) and coated membranes were dried overnight 
in a vacuum oven at room temperature. The next 
day, the membranes were coated 4 times with 5% 
PLGA (PURASORB PDLG 5004A - Corbion 
Group Netherlands B.V.) without testosterone and 
alendronate and dried over 3 days in a vacuum oven 
at room temperature. Coated as well as non-coated 
membranes (controls) were then cut into appropriate 
size (2 x 1 cm) and packed into double Tyvek pouches 
and marked F0, F20, F50 and F125, respectively. 
Final sterilization was performed by gamma 
irradiation with 25 kGy (Synergy Health Ede B.V.; 
Ede, The Netherlands).
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To determine the in vitro release of testosterone, 
F20, F50 and F125 membranes (n = 3) were placed 
in 2.5 ml PBS containing 0.5% sodium dodecyl 
sulphate at 37 °C and at day 1, 7, 14, 21, 28, 35 and 
49 a sample was taken. For determination of total 
content of testosterone, membranes (n = 3) were 
placed in acetonitrile for 60 min to dissolve the PLGA 
coating and the testosterone within. Testosterone 
concentration in PBS (in vitro release) and acetonitrile 
(total content) was determined with high performance 
liquid chromatography (Agilent 6125 - Agilent 
Technologies; Baden-Württemberg, Germany) on 
a ZORBAX Eclipse Plus C18 column (Agilent 
Technologies). In vitro release of alendronate was 
not determined as alendronate was added as a fixed 
amount of 20 μg/cm2 which was validated in previous 
experiments (data not shown). 
Minipig surgical procedures
Sixteen adult Göttingen minipigs were obtained 
from Ellegaard (Dalmose, Denmark) and used as 
experimental animals. All surgical procedures were 
performed at the Radboudumc Animal Research 
facility (Nijmegen, The Netherlands) after the Dutch 
Central Committee on Animal Research and the 
local Ethical Committee on Animal Research of the 
Radboud University approved the study under project 
license AVD1030020185825 and protocol 2018-0004, 
respectively.
Before surgery all animals were given an 
intramuscular injection of 10 mg/kg ketamine 
(Alfasan Co.; Woerden, The Netherlands), midazolam 
(0.6 mg/kg body weight) (Dormicum® injection 
- Roche Laboratories; Almere, the Netherlands) 
and atropine (50 µg/kg body weight) (Centrafarm 
Pharmaceuticals B.V.; Etten-Leur, The Netherlands). 
Also, prophylactic amoxicillin (50 µg/kg body 
weight) (Centrafarm Pharmaceuticals B.V) was 
administered by intravenous (i.v.) infusion. 
General anaesthesia was induced by propofol 
i.v. (2.5 mg/kg body weight) (Fresenius Kabi; 
Hertogenbosch, The Netherlands) and was maintained 
after tracheal intubation with Isoflurane (1.0 - 1.5%) 
(Isoflutek - Laboratorios Karizoo; Barcelona, 
Spain). After shaving and cleaning the surgical sites 
with chlorhexidine (5 mg/ml in 70% ethanol), a 
combination of lidocaine (10 mg/ml) (Fresenius-
Kabi) and bupivacaine (5 mg/ml) (Aurobindo 
Pharma B.V.; Zwijndrecht, The Netherlands) was 
administered at the surgical sites for intraoperative 
analgesia. Then, an extraoral sub-angular incision 
was made bilaterally, exposing the lateral portion of 
the mandibular body and ramus of the minipig. Four 
standardized intraosseous defects measuring 8 mm in 
diameter and 4 mm in depth were made in the anterior 
region of the mandible distal from the first premolar 
(two at the right and two at the left side of the jaw). 
During drilling, sterile saline was used to prevent 
heating of the drill and to protect the surrounding 
bony structures (Figure 1A). The defects were filled 
with Small Geistlich Bio-Oss® granules (0.25 - 1 
mm) (Geistlich Pharma AG; Wolhusen, Switzerland) 
(Figure 1B) and covered with a non-coated or coated 
membrane (all four dosages were applied per animal), 
ensuring that dosages were equally distributed 
between bone defect locations. All membranes were 
fixed at the corners with titanium pins (Straumann 
AG; Basal, Switzerland) (Figure 1C). The soft tissues 
were closed in multiple layers by using resorbable 
sutures (Vicryl® 3-0 and 2-0 - Ethicon; Norderstedt, 
Germany). Immediate postoperative pain was 
controlled by a buprenorphine patch (20 µg/hour) 
(BuTrans® - Mundipharma Pharmaceuticals B.V.; 
Mechelen, Belgium) and meloxycam (5 mg/ml) 
(Novem - Boehringer Ingelheim; Ingelheim am Rhein, 
Germany) was given per 24 hours after surgery. 
The animals were checked daily for any possible 
infections. 
Animals were divided into 2 groups (n = 8) 
Figure 1. Minipig surgical procedures. A = Two 8 mm diameter cylindrical defects were created in the left and right side of the mandible; 
B = the defects were filled with Bio-Oss® granules soaked in blood; C = covered with a collagen membrane which was fixed to the mandible 
by titanium pins. 
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and defects were allowed to heal for 6 and 12 weeks. 
At the end of each designated healing period, animals 
were euthanized. The mandibles were harvested, 
excess soft tissue was removed and with a circular 
saw the apical side was trimmed to remove teeth and 
the mandible was further trimmed to approximately 
4 cm in length. After removal of the marrow the 
mandibles were placed in 4% formaldehyde.
Micro computed tomography analysis
After fixation in 4% formaldehyde for 14 days, the 
specimens were placed in 70% ethanol and μCT 
measurements were performed on a μCT100 imaging 
system (Scanco Medical; Brüttisellen, Switzerland). 
The parameters used for scanning involved an 
isotropic voxel size of 11.4 μm; an energy of 70 
kVp; a current of 200 μA; and an integration time of 
320 ms. Based on the comparison of µCT images to 
corresponding histological sections, thresholds were 
defined to segment new bone and Bio-Oss® granules 
from the images. On a range of 0 - 1000, the threshold 
for new bone was set to 310 - 499 and for Bio-Oss® 
a threshold of 500 - 1000 was used. For the selection 
of new bone, a rod shaped region of interest (ROI) (2 
mm in diameter and 6 mm long) was set, located in 
the top region of the defect and 1mm from the defect 
border, then BV/TV and BMD was assessed in the 
ROI using µCT Analysis Software (Scanco Medical). 
Histological preparation
After performing µCT scanning, the specimens 
were dehydrated in a graded series of ethanol 
(70 - 100%), after which they were embedded 
in polymethylmethacrylate (pMMA). After 
polymerization, thin sections of 15 - 20 μm were 
prepared in a transverse plane perpendicular on 
the longitudinal direction of the mandible using a 
diamond blade microtome (Leica SP 1600 - Leica 
Microsystems; Nussloch, Germany). The first section 
of each specimen was aimed at the center of the defect 
or slightly more on the mesial side of the jaw and 
continued distally. Then, sections of each specimen 
were stained with methylene blue and basic fuchsine. 
At least, three sections of the center area of the defect 
were used for histological histomorphometrical 
analysis.
Descriptive histology and histomorphometrical 
analysis
The pMMA sections of the center area of the defect 
for each implantation time were examined by light 
microscopy (Leica Microsystems AG; Wetzlar, 
Germany). Quantitative assessment of the pMMA 
specimens was performed using computer‐based 
image analysis software - ImageJ® version 2.0.0-rc-
43/1.52n (Fiji distribution; National Institute of Health, 
Bethesda, Meryland, USA). From digitalized images 
of the sections a ROI of 6 x 2 mm was positioned 
in the center and top-region of the defect leaving 
1 mm free of the defect border (Figure 2). When the 
diameter of the defect in the sections had a different 
size, the ROI was adapted accordingly. Within the 
ROI the contours of newly formed bone, Bio-Oss® 
and non- mineralized tissue were drawn manually 
(Wacom Cintiq 16 - Wacom Co., Ltd.; Kazo, Japan). 
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After drawing, the contours were filled, and the 
images were converted to binary images. With the 
measurement function of ImageJ®, total area of 
newly formed bone and Bio-Oss® were subsequently 
measured. 
Statistical analysis
All data are expressed as mean and standard deviation 
(M [SD]). The size of the experimental groups (n) is 
given in parentheses. Differences between groups 
were assessed by paired Student’s t‐test. Statistical 
significance was set at P < 0.05 (two‐tailed) and 
probabilities are indicated by asterisks (*P < 0.05, 




After 7 days of culturing ALP activity in porcine 
biopsies stimulated with a combination of 
dihydrotestosterone and alendronate was significantly 
increased (218 [31]%, P = 0.007, unpaired 
Student’s t-test), while biopsies stimulated with 
dihydrotestosterone or alendronate alone did not 
(Figure 3A). After 28 days of culturing, BV/TV, BS/
TV, Tb.Th and Tb.N were significantly increased (140 
[10]%, P = 0.007, 120 [4]%, P = 0.015, 120 [10]%, 
P = 0.043, 118 [4]%, P = 0.042, respectively, 
Figure 3. Porcine and human femur bone explant stimulated with dihydrotestosterone (DHT) and alendronate (Aln).
A = ALP activity in culture medium of porcine femur bone explants (n = 3) stimulated for 7 days with DHT, Aln or a combination of both.
B and C = 2D µCT reconstruction and (C) µCT analysis of trabecular bone parameters and bone strength of porcine bone explants (n = 3) 
stimulated with DHT and Aln after 28 days compared to a non-stimulated controls; 
D = analysis of trabecular bone parameters of human osteoarthritic femur bone explants stimulated with DHT (n = 65) and Aln (n = 62) 
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unpaired Student’s t-test) when the biopsies were 
stimulated with a combination of dihydrotestosterone 
and alendronate, while Tb.Sp was significantly 
decreased (70 [3]%, P = 0.0003, unpaired Student’s 
t-test) (Figure 3B, C). Additionally, a significant 
increase in bone strength was observed in biopsies 
stimulated with both dihydrotestosterone and 
alendronate (141 [19]%, P = 0.007, unpaired Student’s 
t-test) (Figure 3C).
Human bone specimens
Stimulation of human bone from OA patients with a 
combination of dihydrotestosterone and alendronate 
for 28 days resulted in a significant increase in BMD 
(126 [58]%, P = 0.0084), BV/TV (120 [47]%, P = 
0.016), BS/TV (122 [58]%, P = 0.009, Tb.Th (115 




Analysis of the in vitro release of testosterone from 
the coated membranes revealed that there was no burst 
release of testosterone, as the percentage released 
is 23 (7)%, 19 (1)% and 34 (6)% after 24 hours, for 
F20, F50 and F125 membranes respectively (Figure 
4). Release of testosterone continued over a period of 
3 - 4 weeks. Analysis of total content of testosterone 
showed that the F20, F50 and F125 membranes 
contained 43, 128 and 241 µg of testosterone, 
respectively, which is 7, 28 and 4% from the 
aimed amount of testosterone (40, 100 and 250 µg, 
respectively). 
Clinical findings
Healing was uneventful and no signs of inflammation 
could be observed at the surgical sites. The minipigs 
remained in healthy conditions during the study.
Micro computed tomography
Thresholding of the µCT signal was performed to 
separate Bio-Oss® granules from newly formed 
bone. A corresponding histological section of the 
µCT image was taken to judge for the separation of 
newly formed bone and Bio-Oss® granules (Figure 
5A). Analysis of the µCT signal of the newly formed 
bone showed a significant 19% increase in BV/TV 
(F0; 37 [7]%, F125; 44 [8]%, P = 0.036) and a 9% 
increase in BMD (F0; 724 [93], F125; 792 [64], P = 
0.036) of the F125 treated defects compared to the F0 
Figure 4.  In vitro release of testosterone from testosterone coated 
collagen membranes. Cumulative in vitro release of testosterone 
from F20, F50 and F125 coated membranes (n = 3) over a period 
of 7 weeks.
treated defects after 6 weeks (Figure 5B, C), while 
no significant dose dependent increase in BV/TV and 
BMD for F20 and F50 compared to F0 were observed 
at week 6 (Figure 5B, C). At week 12, no significant 
difference in BV/TV or BMD was observed for any of 
the treatments (Figure 5D, E). 
Histology 
Histological analysis at week 6
Light microscopical analysis of the 6 weeks 
specimens showed that the bone healing response in 
the various experimental groups was very similar. 
The bone defect as well as the Bio-Oss® granules 
could be easily discerned. The bone defects were 
found to be homogeneously filled with Bio-Oss® 
granules and granules were in close vicinity of the 
defect borders and bone was always bridging the 
small space between defect border and the Bio-Oss® 
granules (Figure 6A). Newly formed bone between 
the granules bridged the defect and sometimes callus 
formation at the buccal side was observed (Figure 
6A). Bone was growing in between the Bio-Oss® 
granules and Bio-Oss® granules were covered for 
the major part with bone tissue. No indication for 
an inflammatory response were observed in any of 
the samples analysed (Figure 6B). The bone tissue 
was in close contact with the Bio-Oss® surface 
without an intervening non-mineralized tissue layer 
(Figure 6B). The bone that bridged the defect was 
not mature and had a lamellar appearance (Figure 
6B). In some specimens, the Bio-Oss® granules 
were extending into the bone marrow cavity (Figure 
6C) and ingrowth of new bone covered these 
granules (Figure 6D). Although a large quantity of 
bone was seen in the bone defects, defects were not 
completely closed with bone in some specimens. 
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In those specimens, a gap was present from the buccal 
side into the bone marrow cavity. This gap was always 
filled with non-mineralized tissue. Incomplete bone 
bridging was seen in three defects of the F0-group, in 
one defect of the F20-group, in one defect of the F50 
and one defect of the F125-group. In a few sections, 
remnants of the membrane could be recognized. 
The remnants were surrounded by non-mineralized 
fibrous tissue without evident inflammatory response 
(Figure 6E). In the newly formed bone, voids were 
present, which were filled with bone marrow-like 
non-mineralized fibrous tissue, as characterized 
by the presence of fat tissue, blood vessels and a 
fibrous tissue matrix. The voids showed remodelling 
activity, as confirmed by the presence of osteoid and 
osteoblasts, which were lining the osteoid (Figure 
6F). Occasionally, Bio-Oss® granules penetrated these 
remodelling voids. Such granules were found to be 
covered with osteoclast-like cells (Figure 6F). Still, 
no clear degradation of the Bio-Oss® granules was 
observed.
Histological analysis at week 12
Compared with 6 weeks of implantation, bone 
remodelling had proceeded, and the newly deposited 
Figure 5. Micro-CT analysis of minipig bone defects.
A = By comparing histological sections to corresponding µCT images, thresholds were set to segment new bone from Bio-Oss® granules 
on µCT.
B and D = Bone volume fraction (BV/TV) and (C, E) bone mineral density (BMD) was determined for the new bone formed at (B, C) week 
6 and (D, E) week 12.
Relative increases are shown as percentages within the bars.
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bone had become more mature. Defect borders could 
be easily recognized, but significant remodelling 
of the defect borders had occurred (Figure 7A). The 
straight border, as created by the drilling process, 
had become irregular and osteons had formed close 
to the defect border (Figure 7B). In all defects, the 
Bio-Oss® granules could still be easily discerned. 
The granules were surrounded by the new bone 
(Figure 7C). Additionally, the membrane could no 
longer be recognized, and periosteal bone formation 
(callus) seemed reduced compared with the 6 weeks 
specimens. If the granules extended into the bone 
marrow cavity, then a large amount of bone was 
present around and between the granules (Figure 7D). 
Light microscopical analysis confirmed that there was 
also no indication for an inflammatory response were 
observed in any of the 12-weeks samples (Figure 7E). 
At higher magnification, osteoblasts with associated 
osteoid tissue could be observed at the interface of 
non-mineralized tissue and new bone (Figure 7F, G). 
Figure 6. Histological analysis of bone defects at week 6 (Methylene Blue Basic fuchsin stain, original magnification x400).
A = Histological section of F125 treated defect.
B = High magnification of the boxed area in (A).
C = F125 treated defect showing Bio-Oss® granules extending into the bone marrow.
D = High magnification of boxed area in (C).
E = F20 treated defect showing remnants of the collagen membrane.
F = High magnification of F50 treated defect showing a void where osteoid tissue and osteoblasts lined the newly formed bone and 
osteoclast-like cells lined the surface of Bio-Oss® granules.
Dashed line = defect border; dashed oval = osteon; nb = new bone; cb = cortical bone; bo = Bio-Oss®; nmt = non-mineralized tissue; closed 
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Figure 7. Histological analysis of bone defects at week 12 (Methylene Blue Basic fuchsin stain, original magnification x400).
A = Histological section of F20 treated defect.
B = High magnification of the boxed area in (A), showing an irregular defect border. 
C = High magnification of boxed area of (A), showing Bio-Oss® granules completely surrounded by new bone.
D = F20 treated defect where Bio-Oss® granules extending into the bone marrow cavity.
E = Histological section of a F50 treated defect showing the Bio-Oss® granules within the defect.
F and G = High magnification of a F20 treated defect showing a void where osteoid tissue and osteoblasts lined the newly formed bone.
G and H = Osteoclast-like cells lined the surface of Bio-Oss® granules.
Dashed line = defect border; dashed oval = osteon; nb = new bone; cb = cortical bone; bo = Bio-Oss®; nmt = non-mineralized tissue; closed 
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Simultaneously, osteoclasts were observed on the 
Bio-Oss® surface in locations were the Bio-Oss® 
granules were penetrating a void (Figure 7G, H). The 
presence of osteoid, osteoblasts and osteoclasts in 
the voids indicated that the bone remodelling process 
was still continuing and not inhibited by the released 
testosterone or alendronate.
Quantitative histological analysis of newly formed bone
A ROI of 6 x 2 mm was positioned in the center and 
top of the defect and non-mineralized tissue, Bio-Oss® 
granules and new bone were manually selected, and 
area of the tissues was determined (Figure 2). Analysis 
of the percentage of area of the newly formed bone 
showed a significant 20% increase in area in the F125 
coated membrane treated defects (40 [10]%) compared 
to the F0 treated defects after 6 weeks (33 [10]%, P = 
0.013) (Figure 8A). A dose dependent increase in area 
of new bone for F20 (F20; 35 [7]%) and F50 (F50; 
37 [7]%) compared to F0 was observed at week 6, 
but this was not significant (Figure 8A). At week 12, 
the total % of new bone was increased compared to 
week 6 (F0; 59 [7]%, F20; 59 [5]%, F50; 59 [5]% and 
F125; 58 [4]%), but no increase in newly formed bone 
compared to F0 was observed (Figure 8B). No change 
in area of Bio-Oss® was observed in any of the treated 
groups at week 6 (F0; 33 [7]%, F20; 33 [6]%, F50; 303 
[8]% and F125; 34 [8]%) or week 12 (F0; 29 [6]%, 
F20; 31 [5]%, F50; 30 [4]% and F125; 33 [6]%). 
A more detailed analysis of the 6-week dataset was 
performed to investigate individual responses to 
treatment. For this, the area of new bone in treated 
defects were compared to the area of new bone in the 
corresponding F0 treated defect of the same animal 
and values were normalized to F0 control (100%). 
These data showed that in only 3 out of 8 F20 treated 
defects the area of new bone was increased compared 
to their corresponding F0 treated defects (Figure 9A). 
In the F50 treated defects 5 out of 8 defects showed an 
increase in new bone (Figure 9B), while in the F125 
treated defects all defects showed an increase in new 
bone as compared to the F0 defect and an average 
24% increase in new bone formation was observed 
when values were normalized to F0 controls (100%) 
(Figure 9C).
Figure 9. Increase in new bone relative to paired control defect. The relative increase in a treated defect is normalized to the new bone 
formation in the F0 defect (100%) in the same animal. The number of animals that show an increase are depicted above the dashed line and 
the number of animals that show a reduced new bone formation are shown below the dashed line. The average relative increase in new bone 
in the F125 group is displayed by the open triangle.
Figure 8. Histomorphometric analysis of new bone formation in minipig bone defects. The percentage of newly formed bone in the bone 
defects: A = at week 6; B = at week 12.
Relative increases are shown as percentages within the bars.
BA
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DISCUSSION
Implant placement after tooth extraction can be a 
challenge because of post-extraction bone resorption 
and dimensional changes of the alveolar ridge. 
GBR techniques, using bone substitute materials 
(i.e. bovine-derived xenografts and deproteinized 
bovine bone minerals) in combination with barrier 
membranes have been developed to promote bone 
formation. The goal of the present study was to 
evaluate the bone formation supportive properties 
of porcine derived resorbable collagen membranes 
coated with a PLGA solution containing both 
testosterone and alendronate in ancillary amounts 
and to test the applicability of coated membranes for 
GBR procedures. The in vitro assays with porcine and 
human derived bone specimens demonstrated that the 
combined use of dihydrotestosterone and alendronate 
had a synergistic and significant stimulating effect 
on bone formation and bone strength of the bone 
biopsies. The in vitro drug release study confirmed 
the continuous, sustained release of testosterone 
from the porcine membranes over a period of 3 - 
4 weeks. Finally, the minipig study showed at 6 
weeks a significant increase in bone formation in 
the mandibular defects that were covered with the 
membrane (F125) that was coated with 125 µg/
cm2 testosterone and 20 µg/cm2 alendronate. At 12 
weeks, all bone defects were completely filled and no 
differences in bone formation were observed between 
the treatment groups. 
Current bone regeneration strategies focus on the 
improvement of bone regeneration by drug delivery. 
The major aim is to change the balance in the bone 
remodelling cycle resulting in an enhanced bone 
formation. To achieve this, knowledge is required 
about the bone formation mechanism. Bone explant 
models are very appropriate to initially study the 
effect of pharmacological interventions on bone cell 
response. Using bone explant specimens, cellular 
diversity and spatial distribution of the various bone 
cells is maintained during several weeks of culturing 
and the explants are less costly and more standardized 
than animal models [23-25]. In addition, the bone 
explant culture model allows the use of healthy as 
well as diseased bone biopsies. These advantages 
of the bone explant culture model were evidently 
confirmed in the performed in vitro assays. 
A challenge in the pharmacological improvement of 
bone regeneration is the optimal delivery of ancillary 
amounts of the drug(s). Efficiency of the therapeutic 
effect is achieved by maintaining a sustained and local 
drug release within the vicinity of the bone defect 
[26]. This can be achieved by proper selection of the 
drug carrier. In view of this, PLGA is considered to 
be the polymer of choice for local delivery of small 
molecules to (bone) tissue for a prolonged treatment 
time. For example, PLGA coatings on tubular meshes 
have been applied successfully for the sustained 
release of antibiotics and an anti-restenosis drug 
[27,28]. This corroborates with our in vitro release 
data of PLGA-coated pericard membranes containing 
testosterone and justified the use of these membranes 
in the in vivo study.
For the in vivo study, the mandible of a minipig 
was chosen because of its size and osteogenic 
potential, which allowed the evaluation of different 
treatment options in one animal. The minipig model 
also shows close resemblance to human bone in 
terms of anatomical shape and dimensions, bone 
healing response as well as bone structure [29,30]. 
It is possible to create properly sized defects for a 
standardized evaluation of different bone and tissue 
regeneration modalities. Therefore, the minipig is 
widely used as a ‘proof-of principle’ model [31-33]. 
The current clinical timeline for GBR using Bio-Oss® 
bone grafting material and membrane coverage is 6 
months after which dental implants are installed [34]. 
The quality and quantity of the newly formed bone 
is assessed at the time of implant placement. Since 
the primary goal of the minipig study was to study 
if improved GBR could be achieved, we evaluated 
the healing of bone defects covered with degradable 
pericard membranes coated with various amounts 
of testosterone and a fixed amount of alendronate in 
ancillary amounts vs uncoated membranes at two 
time points (6 and 12 weeks). In the present study, no 
empty defects were created as control group, as the 
current standard approach in GBR involves always the 
placement of a bone grafting material. Histological 
analysis of the retrieved specimens indicated:
• All defects were uniformly filled with 
approximately 33% Bio-Oss® with no significant 
changes between the various treatment groups or 
implantation times.
• Bone defect healing was uneventful with no signs 
of inflammation in any of the samples.
• Bio-Oss® granules were associated with the 
presence of osteoclasts, but degradation of the 
granules proceeded very slowly.
These observations do corroborate with other reports 
about the biological behaviour of Bio-Oss® granules 
[35-36]. Light microscopical images showed that 6 
weeks after implantation still remnants of the pericard 
barrier membrane could be observed, whereas 
the membrane had degraded completely after 12 
weeks. Evidently, membrane degradation proceeded 
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faster in comparison to other studies. For example, 
Tovar et al. [37] used porcine pericardium collagen 
membranes for GBR of furcation defects in beagle 
dogs. The membrane gradually degraded from 
6 to 12 weeks of implantation but was still not 
completely resorbed at 24 weeks. Also Hwang et 
al. [38], who compared commercially available 
collagen membranes from porcine skin with porcine 
pericardium membranes in a rabbit tibial defect 
model, observed that the skin derived membranes 
were almost completely degraded at 12 weeks, while 
the pericardium membranes remained. It has to be 
noticed that the degradation properties of collagen 
membranes are determined by the used processing 
technique for membrane fabrication. Processing 
steps, like sterilization technique and cross-linking, 
will affect the structural properties, which potentially 
can influence the degradation kinetics of a collagen 
membrane. Nevertheless, our histologic outcome 
confirmed that the membrane was maintained long 
enough to perform its barrier function. 
Considering bone formation, the quantified data of 
the defects that contained only Bio-Oss® granules 
and were covered with a non-coated membrane 
showed that the percentage of bone ingrowth at 6 and 
12 weeks of implantation is in agreement with other 
studies [39,40]. On the other hand, a dose dependent 
increase in new bone formation was observed at 
6 weeks for the defects covered with membranes 
coated with alendronate and testosterone. Using 
F125 membranes, new bone formation significantly 
increased up to 24% compared to uncoated 
membranes. At 12 weeks, no significant difference 
in the percentage of bone ingrowth between the 
various groups was observed and all defects showed 
a filling percentage of almost 100% (bone + Bio-
Oss® granules). The sequentially increasing bone 
formation in the bone defects covered with drug 
treated membranes is undoubtedly attributable to the 
release of the alendronate and testosterone, which are 
known to have an improving effect on bone turnover 
and density [17]. The F125 membranes contained 
and released the highest amount of testosterone 
resulting in a significantly increased percentage 
of bone ingrowth. On basis of this finding, it can 
even be assumed that loading the membrane with 
a higher dose of testosterone will perhaps result in a 
further enhancement of bone formation. The lack of 
a difference in defect bone fill between the various 
experimental groups at week 12 is probably due 
to the fact that the defects were not critical-sized, 
which is characterized by spontaneous healing [41]. 
Considering the circular shape, relatively limited size 
and location of the created defect as well as the bone 
healing rate in minipigs, it can be supposed that this 
was the case. The reason that bone grafting is still 
applied in such defects is to stabilize the blood clot 
and to accelerate defect healing. Most likely, this was 
the case in the present study and natural defect closure 
occurred between 8 to 10 weeks of implantation. 
Therefore, at 12 weeks, there will be no further 
stimulating effect on bone formation for the drug 
releasing membranes. 
In addition to the effect of the released alendronate 
and testosterone on the percentage of bone ingrowth 
at 6 weeks, the histological findings revealed that 
bone formation in the defects covered with the drug 
coated membranes appeared to occur from the cortical 
side of the bone defect. In view of this observation, 
an experimental study by Schwartz and co-workers 
[42] described the coverage of bone defects in the 
dog mandible by 6 different barrier membranes. 
Histological analyses demonstrated that angiogenesis 
and bone formation mainly arose from the bottom 
of the defect. Bone healing proceeds via different 
stages. During the repair stage, blood vessels start to 
penetrate into the deposited mineralized matrix and 
adequate blood supply favours the fast progression of 
the ossification process. Consequently, the increased 
bone formation as observed at the cortical side in the 
bone defects covered with coated membranes can 
be indicative that the testosterone and alendronate 
coating can be beneficial for bone formation at the top 
of the defect. 
The maintenance and remodelling of bone is 
depending on the biomechanical loading condition. 
According to Wolff’s Law, bone adapts to the loads 
under which it is placed. Lack of loading in terms 
of duration, magnitude and rate causes that bone 
undergoes adaptative changes of the bone structure, 
e.g. tooth extraction is associated with altered 
functional forces in the dimensions and profile of the 
alveolar ridge [43], The principles of Wolff’s Law 
are also the rationale for the concept of immediate 
and early placement and loading of dental implants. 
Early loading can stimulate osteogenesis and can be 
used to influence the osseointegration of the implant 
as well as to prevent resorption of the alveolar ridge 
[44-46]. However, initial implant stability remains the 
major parameter for final implant success. This is the 
underlying rationale for bone regeneration procedures; 
grafting has to result in bone ingrowth into the defect 
to allow the stable installation of an oral implant. As 
mentioned before, the current waiting time between 
grafting and dental implant placement is 6 months 
and earlier implant installation will result in a reduced 
overall treatment time, which will benefit the patient. 
Considering the enhancing effect of the alendronate 
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and testosterone containing membranes on GBR as 
measured by the presence of newly formed bone, 
these membranes represent a promising development 
for use in the bone regeneration indications or similar 
approaches. Nevertheless, their safety and efficacy will 
have to be proven in a human clinical follow-up study. 
CONCLUSIONS
In conclusion, the data from this in vivo study 
indicate that F125 collagen membranes coated 
with testosterone and alendronate resulted in 
superior bone formation (+24%) when values were 
normalized to control sites using uncoated collagen 
membranes. Normal bone remodelling and no signs 
of inflammation were observed indicating that coated 
membranes with alendronate and testosterone are 
a promising development to optimize the outcome 
and predictability of the bone regeneration approach. 
However, controlled clinical trials are needed to 
prove this. 
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